BioPharma Dive January 13, 2025
Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it’s also unlikely to appease broader investor concerns.
Late last week, Biogen made an unsolicited offer to buy one of its partners, brain drug developer Sage Therapeutics.
The two biotechnology companies have worked together over the past four years on a mood-stabilizing medicine known as Zurzuvae. They split research costs and, after the medicine got approved as a treatment for postpartum depression, began sharing profits.
But Biogen now wants Zurzuvae all to itself. In a Jan. 10 letter to Sage’s top executive Barry Greene, Biogen CEO Christopher Viehbacher wrote that his company’s experience selling nervous system drugs would “enable...
Today's Sponsors
Today's Sponsor